Clinical Trial Update: Rivastigmine for Antimuscarinic Delirium [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating rivastigmine for antimuscarinic delirium due to anticholinergic toxicity has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anticholinergic Toxicity
• Delirium

Drugs mentioned

• Rivastigmine (Rivastigmine)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Anticholinergic Toxicity | Phase 2 | Status: SUSPENDED